Paradigm of biomarkers in metastatic melanoma (Review)

Pekarek,Leonel; Cedra,Alicia Sánchez; Jaudenes,Yumna Dbouk Y.; Ospino,Linda Rocío; Pedrejón,Beatriz Iglesias; Bernier,Loreto; Roberts Cervantes,Eduardo David; Cendra,Cristina Sánchez; Cassinello,Javier; Trasobares,Lidia; Quesada‑Cortés,Alicia; Sáez,Miguel A.; Álvarez‑Mon,Melchor; Ortega,Miguel A.

doi:10.3892/ol.2024.14824

Paradigm of biomarkers in metastatic melanoma (Review)

Authors:
- Leonel Pekarek
- Alicia Sánchez Cedra
- Yumna Dbouk Y. Jaudenes
- Linda Rocío Ospino
- Beatriz Iglesias Pedrejón
- Loreto Bernier
- Eduardo David Roberts Cervantes
- Cristina Sánchez Cendra
- Javier Cassinello
- Lidia Trasobares
- Alicia Quesada‑Cortés
- Miguel A. Sáez
- Melchor Álvarez‑Mon
- Miguel A. Ortega
View Affiliations

Affiliations: Department of Medicine and Medical Specialties, Biomedical Network Research Center on Liver and Digestive Diseases, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain, Oncology Service, University Hospital of Guadalajara, 19002 Guadalajara, Spain
Published online on: November 26, 2024 https://doi.org/10.3892/ol.2024.14824
Article Number: 78
Copyright: © Pekarek et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metastatic melanoma is an aggressive and deadly form of skin cancer, known for its rapid ability to spread to other organs. Melanoma metastasis involves several steps: Local invasion, lymphovascular invasion and proliferation to new sites. This process is facilitated by genetic alterations, interactions with the tumor microenvironment and evasion of the immune system. Despite advances in therapies, the 5‑year survival rate remains low at ~22.5%. Notably, current research is focused on identifying patients who may benefit from specific treatments, considering factors such as mutational load and programmed death ligand 1 expression. BRAF inhibitors and immune checkpoint inhibitors have improved survival, although numerous patients do not respond or develop resistance, underscoring the need for novel biomarkers to optimize treatment and monitoring of the disease. In summary, the purpose of the present article is to review the different serological, histological, microRNA and circulating tumor cell biomarkers that have proven useful in the diagnosis, follow‑up and prognosis of metastatic melanoma. These biomarkers represent a promising area for research and clinical application, with the aim of offering more precise and personalized treatments.

View Figures

View References

1	Arnold M, Singh D, Laversanne M, Vignat J, Vaccarella S, Meheus F, Cust AE, de Vries E, Whiteman DC and Bray F: Global burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatol. 158:495–503. 2022. View Article : Google Scholar : PubMed/NCBI
2	Conforti C and Zalaudek I: Epidemiology and risk factors of melanoma: A review. Dermatol Pract Concept. 11 (Suppl 1):e2021161S2021. View Article : Google Scholar : PubMed/NCBI
3	Dzwierzynski WW: Risk factors and prevention of melanoma. Clin Plast Surg. 48:543–550. 2021. View Article : Google Scholar : PubMed/NCBI
4	Kahlon N, Doddi S, Yousif R, Najib S, Sheikh T, Abuhelwa Z, Burmeister C and Hamouda DM: Treatments for melanoma and mortality rate trends in the U.S., 1975 to 2019. JAMA Netw Open. 5:e22452692022. View Article : Google Scholar : PubMed/NCBI
5	Reitmajer M, Leiter U, Nanz L, Amaral T, Flatz L, Garbe C and Forschner A: Long-term survival of patients with stage IV melanoma: Evaluation of 640 patients with melanoma who entered stage IV between 2014 and 2017. J Cancer Res Clin Oncol. 150:152024. View Article : Google Scholar : PubMed/NCBI
6	Saginala K and Barsouk A, Aluru JS, Rawla P and Barsouk A: Epidemiology of melanoma. Med Sci (Basel). 9:632021.PubMed/NCBI
7	Switzer B, Piperno-Neumann S, Lyon J, Buchbinder E and Puzanov I: Evolution of the treatment of stage IV melanoma. Am Soc Clin Oncol Educ Book. 43:e3974782023. View Article : Google Scholar : PubMed/NCBI
8	Mancuso F, Lage S, Rasero J, Díaz-Ramón JL, Apraiz A, Pérez-Yarza G, Ezkurra PA, Penas C, Sánchez-Diez A, García-Vazquez MD, et al: Serum markers improve current prediction of metastasis development in early-stage melanoma patients: A machine learning-based study. Mol Oncol. 14:1705–1718. 2020. View Article : Google Scholar : PubMed/NCBI
9	Irurzun-Arana I, Asín-Prieto E, Martín-Algarra S and Trocóniz IF: Predicting circulating biomarker response and its impact on the survival of advanced melanoma patients treated with adjuvant therapy. Sci Rep. 10:74782020. View Article : Google Scholar : PubMed/NCBI
10	Karagiannis P, Fittall M and Karagiannis SN: Evaluation of biomarkers in melanoma. Front Oncol. 4:3832015.PubMed/NCBI
11	Paganelli A, Garbarino F, Toto P, Martino GD, D'Urbano M, Auriemma M, Giovanni PD, Panarese F, Staniscia T, Amerio P and Paganelli R: Serological panorama of cytokines in cutaneous melanoma. Cancer Biomark. 26:333–342. 2019. View Article : Google Scholar : PubMed/NCBI
12	Zhao S, Wu D, Wu P, Wang Z and Huang J: Serum IL-10 predicts worse outcome in cancer patients: A meta-analysis. PLoS One. 10:e01395982015. View Article : Google Scholar : PubMed/NCBI
13	Ma YF, Chen C, Li D, Liu M, Lv ZW, Ji Y and Xu J: Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer. Oncotarget. 8:7614–7624. 2017. View Article : Google Scholar : PubMed/NCBI
14	Lin TH, Shao YY, Chan SY, Huang CY, Hsu CH and Cheng AL: High serum transforming growth factor-β1 levels predict outcome in hepatocellular carcinoma patients treated with Sorafenib. Clin Cancer Res. 15:3678–3684. 2015. View Article : Google Scholar : PubMed/NCBI
15	Davey GE, Murmann P, Hoechli M, Tanaka T and Heizmann CW: Calcium-dependent translocation of S100A11 requires tubulin filaments. Biochim Biophys Acta. 1498:220–232. 2000. View Article : Google Scholar : PubMed/NCBI
16	Petersson S, Shubbar E, Enerbäck L and Enerbäck C: Expression patterns of S100 proteins in melanocytes and melanocytic lesions. Melanoma Res. 19:215–225. 2009. View Article : Google Scholar : PubMed/NCBI
17	Oberholzer PA, Urosevic M, Steinert HC and Dummer R: Baseline staging of melanoma with unknown primary site: The value of serum s100 protein and positron emission tomography. Dermatology. 217:351–355. 2008. View Article : Google Scholar : PubMed/NCBI
18	Beyeler M, Waldispuhl S, Strobel K, Joller-Jemelka HI, Burg G and Dummer R: Detection of melanoma relapse: First comparative analysis on imaging techniques versus S100 protein. Dermatology. 213:187–191. 2006. View Article : Google Scholar : PubMed/NCBI
19	Hong IS: Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types. Exp Mol Med. 48:e2422016. View Article : Google Scholar : PubMed/NCBI
20	Viray H, Bradley WR, Schalper KA, Rimm DL and Gould Rothberg BE: Marginal and joint distributions of S100, HMB-45, and Melan-A across a large series of cutaneous melanomas. Arch Pathol Lab Med. 137:1063–1073. 2013. View Article : Google Scholar : PubMed/NCBI
21	Weinstein D, Leininger J, Hamby C and Safai B: Diagnostic and prognostic biomarkers in melanoma. J Clin Aesthet Dermatol. 7:13–24. 2014.PubMed/NCBI
22	Dorizzi RM, Governa M, Tambuscio A, Rizzotti P, Monese C, Minic J and Barisoni D: S100 protein measurement in clinical practice. Clin Biochem. 38:197–198. 2005. View Article : Google Scholar : PubMed/NCBI
23	Rothberg BE, Moeder CB, Kluger H, Halaban R, Elder DE, Murphy GF, Lazar A, Prieto V, Duncan LM and Rimm DL: Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions. Mod Pathol. 21:1121–1129. 2008. View Article : Google Scholar : PubMed/NCBI
24	Ramos-Herberth FI, Karamchandani J, Kim J and Dadras SS: SOX10 immunostaining distinguishes desmoplastic melanoma from excision scar. J Cutan Pathol. 37:944–952. 2010. View Article : Google Scholar : PubMed/NCBI
25	Nonaka D, Chiriboga L and Rubin BP: Sox10: A pan-schwannian and melanocytic marker. Am J Surg Pathol. 32:1291–1298. 2008. View Article : Google Scholar : PubMed/NCBI
26	Vollmer RT: Use of Bayes rule and MIB-1 proliferation index to discriminate Spitz nevus from malignant melanoma. Am J Clin Pathol. 122:499–505. 2004. View Article : Google Scholar : PubMed/NCBI
27	Bobos M: Histopathologic classification and prognostic factors of melanoma: A 2021 update. Ital J Dermatol Venerol. 156:300–321. 2021.PubMed/NCBI
28	Massi D, Brusa D, Merelli B, Ciano M, Audrito V, Serra S, Buonincontri R, Baroni G, Nassini R, Minocci D, et al: PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. Ann Oncol. 25:2433–2442. 2014. View Article : Google Scholar : PubMed/NCBI
29	Berghoff AS, Ricken G, Widhalm G, Rajky O, Dieckmann K, Birner P, Bartsch R, Höller C and Preusser M: Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases. Histopathology. 66:289–299. 2015. View Article : Google Scholar : PubMed/NCBI
30	Chatterjee D and Bhattacharjee R: Immunohistochemistry in dermatopathology and its relevance in clinical practice. Indian Dermatol Online J. 9:234–244. 2018. View Article : Google Scholar : PubMed/NCBI
31	Yang K, Oak ASW, Slominski RM, Brożyna AA and Slominski AT: Current molecular markers of melanoma and treatment targets. Int J Mol Sci. 21:35352020. View Article : Google Scholar : PubMed/NCBI
32	Newton-Bishop J, Bishop DT and Harland M: Melanoma genomics. Acta Derm Venereol. 100:adv001382020. View Article : Google Scholar : PubMed/NCBI
33	Sample A and He YY: Mechanisms and prevention of UV-induced melanoma. Photodermatol Photoimmunol Photomed. 34:13–24. 2018. View Article : Google Scholar : PubMed/NCBI
34	Slominski RM, Chen JY, Raman C and Slominski AT: Photo-neuro-immuno-endocrinology: How the ultraviolet radiation regulates the body, brain, and immune system. Proc Natl Acad Sci USA. 121:e23083741212024. View Article : Google Scholar : PubMed/NCBI
35	Cole MA, Quan T, Voorhees JJ and Fisher GJ: Extracellular matrix regulation of fibroblast function: Redefining our perspective on skin aging. J Cell Commun Signal. 12:35–43. 2018. View Article : Google Scholar : PubMed/NCBI
36	Schneider LA, Raizner K, Wlaschek M, Brenneisen P, Gethöffer K and Scharffetter-Kochanek K: UVA-1 exposure in vivo leads to an IL-6 surge within the skin. Exp Dermatol. 26:830–832. 2017. View Article : Google Scholar : PubMed/NCBI
37	Zorina A, Zorin V, Kudlay D and Kopnin P: Molecular mechanisms of changes in homeostasis of the dermal extracellular matrix: Both involutional and mediated by ultraviolet radiation. Int J Mol Sci. 23:66552022. View Article : Google Scholar : PubMed/NCBI
38	Naylor EC, Watson RE and Sherratt MJ: Molecular aspects of skin ageing. Maturitas. 69:249–256. 2011. View Article : Google Scholar : PubMed/NCBI
39	Kripke ML, Cox PA, Alas LG and Yarosh DB: Pyrimidine dimers in DNA initiate systemic immunosuppression in UV-irradiated mice. Proc Natl Acad Sci USA. 89:7516–7520. 1992. View Article : Google Scholar : PubMed/NCBI
40	González-Púmariega M, Vernhes Tamayo M and Sánchez-Lamar Á: ISSN: 0717-196X simpletheoria@pehuen.chillan.ubiobio.cl. Redalyc.org. 2009.https://www.redalyc.org/pdf/299/29917006006.pdf
41	Ravanat JL, Douki T and Cadet J: Direct and indirect effects of UV radiation on DNA and its components. J Photochem Photobiol B. 63:88–102. 2001. View Article : Google Scholar : PubMed/NCBI
42	Slominski RM, Sarna T, Płonka PM, Raman C, Brożyna AA and Slominski AT: Melanoma, melanin, and melanogenesis: The Yin and Yang relationship. Front Oncol. 12:8424962022. View Article : Google Scholar : PubMed/NCBI
43	Slominski A, Tobin DJ, Shibahara S and Wortsman J: Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev. 84:1155–1228. 2004. View Article : Google Scholar : PubMed/NCBI
44	Moan J, Dahlback A and Setlow RB: Epidemiological support for an hypothesis for melanoma induction indicating a role for UVA radiation. Photochem Photobiol. 70:243–247. 1999. View Article : Google Scholar : PubMed/NCBI
45	Mitra D, Luo X, Morgan A, Wang J, Hoang MP, Lo J, Guerrero CR, Lennerz JK, Mihm MC, Wargo JA, et al: An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature. 491:449–453. 2012. View Article : Google Scholar : PubMed/NCBI
46	Prota G: The chemistry of melanins and melanogenesis. Fortschr Chem Org Naturst. 64:93–148. 1995.PubMed/NCBI
47	Del Bino S, Ito S, Sok J, Nakanishi Y, Bastien P, Wakamatsu K and Bernerd F: Chemical analysis of constitutive pigmentation of human epidermis reveals constant eumelanin to pheomelanin ratio. Pigment Cell Melanoma Res. 28:707–717. 2015. View Article : Google Scholar : PubMed/NCBI
48	Napolitano A, Panzella L, Monfrecola G and d'Ischia M: Pheomelanin-induced oxidative stress: Bright and dark chemistry bridging red hair phenotype and melanoma. Pigment Cell Melanoma Res. 27:721–733. 2014. View Article : Google Scholar : PubMed/NCBI
49	Li C, Kuai L, Cui R and Miao X: Melanogenesis and the targeted therapy of melanoma. Biomolecules. 12:18742022. View Article : Google Scholar : PubMed/NCBI
50	Elder DE, Bastian BC, Cree IA, Massi D and Scolyer RA: The 2018 World Health Organization classification of cutaneous, mucosal, and uveal melanoma: Detailed analysis of 9 distinct subtypes defined by their evolutionary pathway. Arch Pathol Lab Med. 144:500–522. 2020. View Article : Google Scholar : PubMed/NCBI
51	Podlipnik S, Potrony M and Puig S: Genetic markers for characterization and prediction of prognosis of melanoma subtypes: A 2021 update. Ital J Dermatol Venerol. 156:322–330. 2021.PubMed/NCBI
52	Comito G, Giannoni E, Di Gennaro P, Segura CP, Gerlini G and Chiarugi P: Stromal fibroblasts synergize with hypoxic oxidative stress to enhance melanoma aggressiveness. Cancer Lett. 324:31–41. 2012. View Article : Google Scholar : PubMed/NCBI
53	Tímár J and Ladányi A: Molecular pathology of skin melanoma: Epidemiology, differential diagnostics, prognosis and therapy prediction. Int J Mol Sci. 23:53842022. View Article : Google Scholar : PubMed/NCBI
54	Seger R, Seger D, Reszka AA, Munar ES, Eldar-Finkelman H, Dobrowolska G, Jensen AM, Campbell JS, Fischer EH and Krebs EG: Overexpression of mitogen-activated protein kinase kinase (MAPKK) and its mutants in NIH 3T3 cells. Evidence that MAPKK involvement in cellular proliferation is regulated by phosphorylation of serine residues in its kinase subdomains VII and VIII. J Biol Chem. 269:25699–25709. 1994. View Article : Google Scholar : PubMed/NCBI
55	Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, Obenauf AC, Wackernagel W, Green G, Bouvier N, et al: Mutations in GNA11 in uveal melanoma. N Engl J Med. 363:2191–2199. 2010. View Article : Google Scholar : PubMed/NCBI
56	Patel SP, Kim DW, Lacey CL and Hwu P: GNA11 mutation in a patient with cutaneous origin melanoma: A case report. Medicine (Baltimore). 95:e23362016. View Article : Google Scholar : PubMed/NCBI
57	Demenais F, Mohamdi H, Chaudru V, Goldstein AM, Newton Bishop JA, Bishop DT, Kanetsky PA, Hayward NK, Gillanders E, Elder DE, et al: Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study. J Natl Cancer Inst. 102:1568–1583. 2010. View Article : Google Scholar : PubMed/NCBI
58	Florell SR, Meyer LJ, Boucher KM, Porter-Gill PA, Hart M, Erickson J, Cannon-Albright LA, Pershing LK, Harris RM, Samlowski WE, et al: Longitudinal assessment of the nevus phenotype in a melanoma kindred. J Invest Dermatol. 123:576–582. 2004. View Article : Google Scholar : PubMed/NCBI
59	Helgadottir H, Höiom V, Tuominen R, Nielsen K, Jönsson G, Olsson H and Hansson J: Germline CDKN2A mutation status and survival in familial melanoma cases. J Natl Cancer Inst. 108:djw1352016. View Article : Google Scholar : PubMed/NCBI
60	Rai K, Pilarski R, Boru G, Rehman M, Saqr AH, Massengill JB, Singh A, Marino MJ, Davidorf FH, Cebulla CM and H Abdel-Rahman M: Germline BAP1 alterations in familial uveal melanoma. Genes Chromosomes Cancer. 56:168–174. 2017. View Article : Google Scholar : PubMed/NCBI
61	Colston K, Colston MJ and Feldman D: 1,25-Dihydroxyvitamin D3 and malignant melanoma: The presence of receptors and inhibition of cell growth in culture. Endocrinology. 108:1083–1086. 1981. View Article : Google Scholar : PubMed/NCBI
62	Brożyna AA, Jóźwicki W and Slominski AT: Decreased VDR expression in cutaneous melanomas as marker of tumor progression: New data and analyses. Anticancer Res. 34:2735–2743. 2014.PubMed/NCBI
63	Fargnoli MC, Gandini S, Peris K, Maisonneuve P and Raimondi S: MC1R variants increase melanoma risk in families with CDKN2A mutations: A meta-analysis. Eur J Cancer. 46:1413–1420. 2010. View Article : Google Scholar : PubMed/NCBI
64	Guo R, Franco-Palacios M, Russell M, Goddard L, Hassell L, Gillies E and Fung KM: Micropthalmia transcription factor (MITF) as a diagnostic marker for metastatic melanomas negative for other melanoma markers. Int J Clin Exp Pathol. 6:1658–1664. 2013.PubMed/NCBI
65	Carreira S, Goodall J, Denat L, Rodriguez M, Nuciforo P, Hoek KS, Testori A, Larue L and Goding CR: Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev. 20:3426–3439. 2006. View Article : Google Scholar : PubMed/NCBI
66	Hartman ML and Czyz M: MITF in melanoma: Mechanisms behind its expression and activity. Cell Mol Life Sci. 72:1249–1260. 2015. View Article : Google Scholar : PubMed/NCBI
67	Lister JA, Capper A, Zeng Z, Mathers ME, Richardson J, Paranthaman K, Jackson IJ and Elizabeth Patton E: A conditional zebrafish MITF mutation reveals MITF levels are critical for melanoma promotion vs regression in vivo. J Invest Dermatol. 134:133–140. 2014. View Article : Google Scholar : PubMed/NCBI
68	Hartman ML, Talar B, Noman MZ, Gajos-Michniewicz A, Chouaib S and Czyz M: Gene expression profiling identifies microphthalmia-associated transcription factor (MITF) and Dickkopf-1 (DKK1) as regulators of microenvironment-driven alterations in melanoma phenotype. PLoS One. 9:e951572014. View Article : Google Scholar : PubMed/NCBI
69	Johannessen CM, Johnson LA, Piccioni F, Townes A, Frederick DT, Donahue MK, Narayan R, Flaherty KT, Wargo JA, Root DE and Garraway LA: A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature. 504:138–142. 2013. View Article : Google Scholar : PubMed/NCBI
70	Kaur A, Ecker BL, Douglass SM, Kugel CH III, Webster MR, Almeida FV, Somasundaram R, Hayden J, Ban E, Ahmadzadeh H, et al: Remodeling of the collagen matrix in aging skin promotes melanoma metastasis and affects immune cell motility. Cancer Discov. 9:64–81. 2019. View Article : Google Scholar : PubMed/NCBI
71	Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH III, Dang VM, Appleton J, O'Connell MP, Cheng P, et al: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature. 532:250–254. 2016. View Article : Google Scholar : PubMed/NCBI
72	Heidenreich B, Nagore E, Rachakonda PS, Garcia-Casado Z, Requena C, Traves V, Becker J, Soufir N, Hemminki K and Kumar R: Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma. Nat Commun. 5:34012014. View Article : Google Scholar : PubMed/NCBI
73	Holderfield M, Deuker MM, McCormick F and McMahon M: Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer. 14:455–467. 2014. View Article : Google Scholar : PubMed/NCBI
74	Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al: Mutations of the BRAF gene in human cancer. Nature. 417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
75	Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, Kefford RF, Scolyer RA and Long GV: Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res. 18:3242–3249. 2012. View Article : Google Scholar : PubMed/NCBI
76	Lee JH, Choi JW and Kim YS: Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol. 164:776–784. 2011. View Article : Google Scholar : PubMed/NCBI
77	Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Kim KB, et al: NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 118:4014–4023. 2012. View Article : Google Scholar : PubMed/NCBI
78	Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, et al: KIT as a therapeutic target in metastatic melanoma. JAMA. 305:23272011. View Article : Google Scholar : PubMed/NCBI
79	Escandell I, Martín JM and Jordá E: Novel immunologic approaches to melanoma treatment. Actas Dermosifiliogr. 108:708–720. 2017.(In English, Spanish). View Article : Google Scholar : PubMed/NCBI
80	Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, et al: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 192:1027–1034. 2000. View Article : Google Scholar : PubMed/NCBI
81	Pistillo MP, Fontana V, Morabito A, Dozin B, Laurent S, Carosio R, Banelli B, Ferrero F, Spano L, Tanda E, et al: Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: An Italian melanoma intergroup study. Cancer Immunol Immunother. 68:97–107. 2019. View Article : Google Scholar : PubMed/NCBI
82	Slominski RM, Kim TK, Janjetovic Z, Brożyna AA, Podgorska E, Dixon KM, Mason RS, Tuckey RC, Sharma R, Crossman DK, et al: Malignant melanoma: An overview, new perspectives, and vitamin D signaling. Cancers Basel). 16:22622024. View Article : Google Scholar : PubMed/NCBI
83	Marsavela G, Aya-Bonilla CA, Warkiani ME, Gray ES and Ziman M: Melanoma circulating tumor cells: Benefits and challenges required for clinical application. Cancer Lett. 424:1–8. 2018. View Article : Google Scholar : PubMed/NCBI
84	Shoji Y, Bustos MA, Gross R and Hoon DSB: Recent developments of circulating tumor cell analysis for monitoring cutaneous melanoma patients. Cancers (Basel). 14:8592022. View Article : Google Scholar : PubMed/NCBI
85	Aya-Bonilla CA, Morici M, Hong X, McEvoy AC, Sullivan RJ, Freeman J, Calapre L, Khattak MA, Meniawy T, Millward M, et al: Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells. Br J Cancer. 122:1059–1067. 2020. View Article : Google Scholar : PubMed/NCBI
86	Lin SY, Chang SC, Lam S, Irene Ramos R, Tran K, Ohe S, Salomon MP, Bhagat AAS, Teck Lim C, Fischer TD, et al: Prospective molecular profiling of circulating tumor cells from patients with melanoma receiving combinatorial immunotherapy. Clin Chem. 66:169–177. 2020. View Article : Google Scholar : PubMed/NCBI
87	Li J, Fu W, Zhang W and Li P: High number of circulating tumor cells predicts poor survival of cutaneous melanoma patients in China. Med Sci Monit. 24:324–331. 2018. View Article : Google Scholar : PubMed/NCBI
88	Hoon DS, Wang Y, Dale PS, Conrad AJ, Schmid P, Garrison D, Kuo C, Foshag LJ, Nizze AJ and Morton DL: Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol. 13:2109–2116. 1995. View Article : Google Scholar : PubMed/NCBI
89	Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Robinson WA, Amatruda TT, Kuo C, Wang HJ, Milford R, Morton DL and Hoon DS: Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin Cancer Res. 12:1137–1143. 2006. View Article : Google Scholar : PubMed/NCBI
90	Koyanagi K, O'Day SJ, Boasberg P, Atkins MB, Wang HJ, Gonzalez R, Lewis K, Thompson JA, Anderson CM, Lutzky J, et al: Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res. 16:2402–2408. 2010. View Article : Google Scholar : PubMed/NCBI
91	Kang YT, Mutukuri A, Hadlock T, Fairbairn H, Carle TR, Fouladdel S, Murlidhar V, Kramer A, De Silva Reguera M, Azizi E, et al: Isolation of circulating tumor cells to diagnose melanoma and evaluate the efficacy of surgical resection using melanoma-specific microsystem. Adv Nanobiomed Res. 2:21000832022. View Article : Google Scholar : PubMed/NCBI
92	Lee RC, Feinbaum RL and Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
93	Peng Q and Wang J: Non-coding RNAs in melanoma: Biological functions and potential clinical applications. Mol Ther Oncolytics. 22:219–231. 2021. View Article : Google Scholar : PubMed/NCBI
94	Nakahara S, Fukushima S, Okada E, Morinaga J, Kubo Y, Tokuzumi A, Matsumoto S, Tsuruta-Kadohisa M, Kimura T, Kuriyama H, et al: MicroRNAs that predict the effectiveness of anti-PD-1 therapies in patients with advanced melanoma. J Dermatol Sci. 97:77–79. 2020. View Article : Google Scholar : PubMed/NCBI
95	Dror S, Sander L, Schwartz H, Sheinboim D, Barzilai A, Dishon Y, Apcher S, Golan T, Greenberger S, Barshack I, et al: Melanoma miRNA trafficking controls tumour primary niche formation. Nat Cell Biol. 18:1006–1017. 2016. View Article : Google Scholar : PubMed/NCBI
96	Li Q, Zhang D, Wang Y, Sun P, Hou X, Larner J, Xiong W and Mi J: MiR-21/Smad 7 signaling determines TGF-β1-induced CAF formation. Sci Rep. 3:20382013. View Article : Google Scholar : PubMed/NCBI
97	Heinemann A, Zhao F, Pechlivanis S, Eberle J, Steinle A, Diederichs S, Schadendorf D and Paschen A: Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D. Cancer Res. 72:460–471. 2012. View Article : Google Scholar : PubMed/NCBI
98	Segura MF, Hanniford D, Menendez S, Reavie L, Zou X, Alvarez-Diaz S, Zakrzewski J, Blochin E, Rose A, Bogunovic D, et al: Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci USA. 106:1814–1819. 2009. View Article : Google Scholar : PubMed/NCBI
99	Liu S, Tetzlaff MT, Wang T, Yang R, Xie L, Zhang G, Krepler C, Xiao M, Beqiri M, Xu W, et al: miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment. Pigment Cell Melanoma Res. 28:431–441. 2015. View Article : Google Scholar : PubMed/NCBI
100	Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, et al: Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol. 40:127–137. 2022. View Article : Google Scholar : PubMed/NCBI
101	Nguyen MT, Luo YH, Li AL, Tsai JC, Wu KL, Chung PJ and Ma N: miRNA as a Modulator of Immunotherapy and Immune Response in Melanoma. Biomolecules. 11:16482021. View Article : Google Scholar : PubMed/NCBI
102	Fawzy MS, Ibrahiem AT, Bayomy NA, Makhdoom AK, Alanazi KS, Alanazi AM, Mukhlef AM and Toraih EA: MicroRNA-155 and disease-related immunohistochemical parameters in cutaneous melanoma. Diagnostics (Basel). 13:12052023. View Article : Google Scholar : PubMed/NCBI
103	Martinez-Usatorre A, Sempere LF, Carmona SJ, Carretero-Iglesia L, Monnot G, Speiser DE, Rufer N, Donda A, Zehn D, Jandus C and Romero P: MicroRNA-155 expression is enhanced by T-cell receptor stimulation strength and correlates with improved tumor control in melanoma. Cancer Immunol Res. 7:1013–1024. 2019. View Article : Google Scholar : PubMed/NCBI
104	Dong L, Tian X, Zhao Y, Tu H, Wong A and Yang Y: The roles of miRNAs (MicroRNAs) in melanoma immunotherapy. Int J Mol Sci. 23:147752022. View Article : Google Scholar : PubMed/NCBI
105	Scheau C, Draghici C, Ilie MA, Lupu M, Solomon I, Tampa M, Georgescu SR, Caruntu A, Constantin C, Neagu M and Caruntu C: Neuroendocrine factors in melanoma pathogenesis. Cancers (Basel). 13:22772021. View Article : Google Scholar : PubMed/NCBI
106	Slominski RM, Raman C, Chen JY and Slominski AT: How cancer hijacks the body's homeostasis through the neuroendocrine system. Trends Neurosci. 46:263–275. 2013. View Article : Google Scholar : PubMed/NCBI